Literature DB >> 15565145

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.

Ildiko Bock-Marquette1, Ankur Saxena, Michael D White, J Michael Dimaio, Deepak Srivastava.   

Abstract

Heart disease is a leading cause of death in newborn children and in adults. Efforts to promote cardiac repair through the use of stem cells hold promise but typically involve isolation and introduction of progenitor cells. Here, we show that the G-actin sequestering peptide thymosin beta4 promotes myocardial and endothelial cell migration in the embryonic heart and retains this property in postnatal cardiomyocytes. Survival of embryonic and postnatal cardiomyocytes in culture was also enhanced by thymosin beta4. We found that thymosin beta4 formed a functional complex with PINCH and integrin-linked kinase (ILK), resulting in activation of the survival kinase Akt (also known as protein kinase B). After coronary artery ligation in mice, thymosin beta4 treatment resulted in upregulation of ILK and Akt activity in the heart, enhanced early myocyte survival and improved cardiac function. These findings suggest that thymosin beta4 promotes cardiomyocyte migration, survival and repair and the pathway it regulates may be a new therapeutic target in the setting of acute myocardial damage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15565145     DOI: 10.1038/nature03000

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  225 in total

1.  PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha.

Authors:  Iris Eke; Ulrike Koch; Stephanie Hehlgans; Veit Sandfort; Fabio Stanchi; Daniel Zips; Michael Baumann; Anna Shevchenko; Christian Pilarsky; Michael Haase; Gustavo B Baretton; Véronique Calleja; Banafshé Larijani; Reinhard Fässler; Nils Cordes
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 2.  Reverse remodeling in heart failure--mechanisms and therapeutic opportunities.

Authors:  Norimichi Koitabashi; David A Kass
Journal:  Nat Rev Cardiol       Date:  2011-12-06       Impact factor: 32.419

3.  Thymosin beta4: a candidate for treatment of stroke?

Authors:  Daniel C Morris; Michael Chopp; Li Zhang; Zheng G Zhang
Journal:  Ann N Y Acad Sci       Date:  2010-04       Impact factor: 5.691

4.  Thymosin beta4: a key factor for protective effects of eEPCs in acute and chronic ischemia.

Authors:  Rabea Hinkel; Ildiko Bock-Marquette; Antonis K Hatzopoulos; Antonis K Hazopoulos; Christian Kupatt
Journal:  Ann N Y Acad Sci       Date:  2010-04       Impact factor: 5.691

5.  Thymosin-β4 (Tβ4) blunts PDGF-dependent phosphorylation and binding of AKT to actin in hepatic stellate cells.

Authors:  Karina Reyes-Gordillo; Ruchi Shah; Anastas Popratiloff; Sidney Fu; Anna Hindle; Frederick Brody; Marcos Rojkind
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 6.  Epicardial progenitor cells in cardiac development and regeneration.

Authors:  Jan Schlueter; Thomas Brand
Journal:  J Cardiovasc Transl Res       Date:  2012-06-01       Impact factor: 4.132

7.  Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke.

Authors:  D C Morris; M Chopp; L Zhang; M Lu; Z G Zhang
Journal:  Neuroscience       Date:  2010-08-25       Impact factor: 3.590

Review 8.  The cardiac hypoxic niche: emerging role of hypoxic microenvironment in cardiac progenitors.

Authors:  Wataru Kimura; Hesham A Sadek
Journal:  Cardiovasc Diagn Ther       Date:  2012-12

Review 9.  Cardioprotective signaling by endothelin.

Authors:  Anita Schorlemmer; Michelle L Matter; Ralph V Shohet
Journal:  Trends Cardiovasc Med       Date:  2008-10       Impact factor: 6.677

10.  The pseudoactive site of ILK is essential for its binding to alpha-Parvin and localization to focal adhesions.

Authors:  Koichi Fukuda; Sudhiranjan Gupta; Ka Chen; Chuanyue Wu; Jun Qin
Journal:  Mol Cell       Date:  2009-12-11       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.